

APPENDIX C

Claim Limitation	Support in 1989 GB Application
28. A humanized immunoglobulin having complementarity determining regions (CDRs) from a donor immunoglobulin and heavy and light chain variable region frameworks from human acceptor immunoglobulin heavy and light chains	See page 1, lines 1-2 and 10-20; page 5, lines 8, to page 6, line 4; , and page 8.
which humanized immunoglobulin specifically binds to an antigen with an effective antigen binding affinity	See page 5, lines 1-7; page 22, lines 27-35, page 23, lines 5-9, page 24, lines 1-4; page 25, lines 27-33; page 26 last paragraph.
wherein said humanized immunoglobulin comprises amino acids from the donor immunoglobulin framework outside both the Kabat CDRs and the structural loop CDRs of the variable regions,	See page 5, lines 1-7; page 26, last paragraph, to page 27, top paragraph.
wherein the donor amino acids replace corresponding amino acids in the acceptor immunoglobulin heavy or light chain frameworks,	See page 5, line 8, to page 6, line 4: page 7, lines 5-20.

and each of said donor amino acids is adjacent to a CDR in the donor immunoglobulin sequence.	See page 7, lines 11-14, showing that homology is maximized between donor and acceptor sequences adjacent CDRs within acceptor framework. At p.5, l. 9-16, reference is made to heavy chain "framework comprises donor at least one of residues 6, 23 and/or 24, 48 and/or 49...." Residue 49 is immediately adjacent CDR2/H2 loop region. On Figs.20-21 residues marked "N" are near or adjacent a CDR.
29. A humanized immunoglobulin according to claim 28 which specifically binds to an antigen with a binding affinity as binding as a chimeric antibody formed from said donor immunoglobulin.	Page 23, lines 1-10; Fig. 29B.
30. A humanized immunoglobulin according to claim 28, wherein the antigen is a human CD3 T-cell receptor.	Page 11, lines 14-21. Page 17, lines 1-8; page 24, bottom paragraph.
31. A humanized immunoglobulin according to claim 28, wherein the donor immunoglobulin is the anti-CD3 T-cell receptor antibody.	Page 17, lines 1-8; page 24, bottom paragraph.